The CTX Human Neural Stem Cell Line and the PISCES Stroke Trial

Muir, K. W. and Sinden, J. D. (2015) The CTX Human Neural Stem Cell Line and the PISCES Stroke Trial. In: Hess, D. C. (ed.) Cell Therapy for Brain Injury. Springer, pp. 111-128. ISBN 9783319150628 (doi: 10.1007/978-3-319-15063-5_8)

Full text not currently available from Enlighten.


The human neural Stem Cell line CTX has been genetically modified with the c-myc-ERTAM construct to allow large-scale production of a uniform allogeneic cell therapy suitable for clinical use. Studies in rodent models of focal cerebral ischaemia reproducibly demonstrate dose-dependent enhancement of sensorimotor recovery when implanted by stereotaxic intracerebral injection in the striatum, with stimulation of endogenous angiogenesis and neurogenesis rather than long-term functional engraftment of cells representing the most likely mechanism of action. The phase I clinical safety trial pilot investigation of human neural stem cells in stroke (PISCES) undertook stereotaxic intraputaminal implantation of CTX cells in doses of up to 20 million cells in 11 participants with chronic disabling ischemic stroke and has identified no cell-related safety concerns to date. A phase II clinical study is underway.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Muir, Professor Keith
Authors: Muir, K. W., and Sinden, J. D.
College/School:College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience

University Staff: Request a correction | Enlighten Editors: Update this record